Preventive Cardiology & Cardiometabolic Health in Portland & Lake Oswego

Heart disease often develops quietly. A person can feel well, exercise regularly, and have no obvious symptoms while cardiovascular risk has been building for years.

At HormoneSynergy®, preventive cardiology begins by trying to understand what that risk actually consists of.

Cholesterol matters, but cholesterol alone is not the whole picture. ApoB particle burden, lipoprotein(a), triglycerides, insulin resistance, blood pressure, inflammation, visceral fat, family history, smoking, sleep, physical fitness, and existing plaque can all change the clinical picture.

The purpose of testing is not to collect more numbers. It is to determine which risks are present, whether disease can already be detected, and what can reasonably be changed.

Who We Help

Preventive cardiovascular evaluation may be useful for people with elevated LDL cholesterol or ApoB, increased lipoprotein(a), high triglycerides, insulin resistance, hypertension, a family history of premature cardiovascular disease, increasing coronary calcium, or cardiovascular findings that do not seem to fit the rest of their health profile.

We also see people who appear metabolically healthy but have unexpectedly high LDL-C or ApoB, as well as patients whose routine cholesterol panel looks acceptable despite other evidence of cardiovascular risk.

Midlife hormone changes, menopause, changing body composition, weight gain, declining insulin sensitivity, sleep apnea, and loss of physical fitness can also alter cardiovascular risk over time.

LDL-C and ApoB Tell Us Different Things

LDL-C measures the amount of cholesterol carried inside LDL particles.

ApoB gives us a practical estimate of the number of atherogenic particles circulating in the bloodstream. This includes LDL, IDL, VLDL remnants, and lipoprotein(a).

Most of the time LDL-C and ApoB move together. Sometimes they do not.

A person can have an LDL-C that appears fairly ordinary while carrying more ApoB-containing particles than expected. This is particularly common in insulin resistance and higher-triglyceride states, where particles may carry less cholesterol individually while particle number rises.

The reverse pattern is also important. Some lean, active, insulin-sensitive people have very high LDL-C. If ApoB is also markedly elevated, a favorable fasting insulin or triglyceride level does not make the ApoB result disappear.

The 2026 ACC/AHA dyslipidemia guideline identifies LDL-C of 190 mg/dL or higher and/or ApoB of 140 mg/dL or higher as severe hypercholesterolemia associated with high lifetime atherosclerotic cardiovascular risk.

For a more detailed discussion, read ApoB vs LDL-C: What Actually Matters for Cardiovascular Risk?

Triglycerides and Remnant Particles

Triglycerides deserve more attention than they often receive on a routine lipid panel.

Insulin resistance can increase production of triglyceride-rich VLDL particles and alter the way cholesterol and triglycerides are distributed among VLDL, LDL, and HDL. Remnant particles can also contribute directly to atherosclerotic risk.

This is one reason we do not interpret ApoB without looking at triglycerides and metabolic health.

Low triglycerides are generally favorable. High triglycerides may point toward insulin resistance, remnant burden, excess alcohol intake, fatty liver, dietary factors, or other metabolic problems. Neither pattern should be interpreted in isolation.

Related reading: Triglyceride-to-HDL Ratio and Longevity Medicine and Remnant Cholesterol and Cardiovascular Risk.

Lipoprotein(a): Risk You Cannot See on a Standard Lipid Panel

Lipoprotein(a), or Lp(a), is an inherited ApoB-containing lipoprotein that can increase cardiovascular risk even in people with an excellent lifestyle.

Because Lp(a) is largely genetically determined, someone can eat well, exercise, maintain a healthy weight, and still have a substantially elevated level.

Knowing that information can change how aggressively the rest of the risk profile is evaluated and managed, particularly when there is premature cardiovascular disease in the family or more plaque than expected for age.

Related reading: Lipoprotein(a) and Cardiovascular Risk.

Metabolic Health Is Cardiovascular Health

Insulin resistance is not only a diabetes issue.

It can influence triglycerides, remnant particles, ApoB, blood pressure, visceral fat, inflammatory signaling, fatty liver risk, and vascular function years before fasting glucose reaches the diabetic range.

Depending on the patient, we may evaluate fasting insulin, glucose, hemoglobin A1c, HOMA-IR, triglycerides, visceral fat, waist distribution, and other metabolic markers together rather than waiting for one laboratory value to cross a diagnostic threshold.

A lean person with good insulin sensitivity and a person with visceral obesity, hypertension, and diabetes do not have identical cardiovascular risk simply because their LDL-C happens to be the same.

Metabolic health modifies cardiovascular risk. It does not make markedly elevated ApoB, Lp(a), hypertension, smoking, or existing plaque irrelevant.

Explore Metabolic Health and Longevity Medicine.

Blood Tests Measure Risk. Imaging Looks for Disease.

Laboratory testing and cardiovascular imaging answer different questions.

ApoB, LDL-C, Lp(a), triglycerides, blood pressure, glucose regulation, and inflammatory markers help describe ongoing exposure and risk.

Imaging can help determine whether atherosclerosis can already be seen.

A normal scan does not make a major risk factor harmless. A young person with very high ApoB may not yet have accumulated enough plaque to produce an abnormal scan. In the same way, someone whose cholesterol has improved today may already carry plaque from decades of previous exposure.

We use imaging when the result is likely to provide information that changes the clinical discussion.

Coronary Artery Calcium: Looking for Calcified Plaque

A coronary artery calcium scan, or CAC, is a noncontrast CT scan that measures calcified plaque in the coronary arteries.

It can be a useful risk-refinement tool in selected patients because it provides evidence that coronary atherosclerosis is already present.

A CAC score of zero is reassuring in the right clinical setting, but it means that no calcified coronary plaque was detected. It does not prove that no coronary plaque exists.

Noncalcified plaque can be present before enough calcium develops to produce a positive calcium score, particularly in younger people and some higher-risk patients.

CCTA and Cleerly® Plaque Analysis

Coronary CT angiography, or CCTA, is different from a calcium scan. CCTA uses intravenous contrast to visualize the coronary arteries and can show both calcified and noncalcified plaque as well as coronary narrowing.

Cleerly® is not a separate scan. It is an AI-assisted analysis applied to suitable CCTA images. The analysis can quantify total plaque burden, plaque composition, distribution, and stenosis.

This can be useful when the clinical question goes beyond whether calcified plaque is present and requires a more detailed look at coronary atherosclerosis.

CCTA with Cleerly® analysis is not automatically the right test for everyone. Age, symptoms, kidney function, contrast allergy, prior imaging, radiation exposure, existing cardiovascular disease, and whether the result is likely to change treatment all matter.

Learn more about Cleerly® CCTA Heart Plaque Testing in Portland.

Carotid Ultrasound and VasoLabs®

Coronary imaging is not the only way to look for vascular disease.

Carotid ultrasound can evaluate plaque in the carotid arteries and measure carotid intima-media thickness, or CIMT. This provides another window into vascular health and can be useful for establishing a baseline or following selected patients over time.

At HormoneSynergy®, VasoLabs® carotid ultrasound may include plaque assessment and CIMT measurement as part of a broader cardiovascular evaluation.

Learn more about VasoLabs® Advanced Cardiovascular Screening.

Body Composition Belongs in the Cardiovascular Conversation

Body weight alone tells us surprisingly little about cardiometabolic health.

Visceral fat is strongly associated with insulin resistance and cardiometabolic risk. Loss of muscle can worsen glucose disposal and metabolic resilience even when body weight has not changed very much.

DEXA and SECA body composition testing can help identify changes in lean mass, fat mass, and visceral fat that are not visible on a standard scale.

These tests do not diagnose coronary disease. They help us understand part of the metabolic environment in which cardiovascular disease develops.

Explore DEXA Body Composition, Bone Density, and Visceral Fat.

What Happens When Risk Is Identified?

The value of finding risk early is having time to change the trajectory.

For some patients, the most important work involves nutrition, resistance training, aerobic conditioning, weight reduction, smoking cessation, better sleep, reducing visceral fat, improving insulin sensitivity, or treating hypertension.

For others, lipid-lowering medication may be appropriate. Depending on the clinical situation, options can include statins, ezetimibe, bempedoic acid, PCSK9-directed therapies, or other evidence-based treatment.

The presence of plaque, severity of ApoB or LDL elevation, Lp(a), age, family history, metabolic health, medication tolerance, kidney function, and overall cardiovascular risk all influence that decision.

We do not use the same treatment threshold or the same treatment plan for every patient.

Our Approach to Cholesterol Treatment

The cholesterol conversation has become unnecessarily polarized.

One side sometimes treats LDL as if it explains every cardiovascular event. The other treats good metabolic health as if it makes elevated ApoB irrelevant.

Neither approach is adequate for an individual patient.

A person can have excellent metabolic health and still have an important inherited lipid problem. A person can have an acceptable LDL-C and substantial particle burden because ApoB is elevated. A person with modest cholesterol numbers can have significant coronary plaque. Another can have multiple risk factors and no detectable plaque yet.

Our job is to understand which situation is actually in front of us.

Preventive Cardiology as Part of Longevity Medicine

Cardiovascular disease does not exist separately from the rest of physiology.

Insulin resistance affects lipoproteins. Visceral fat affects inflammation. Sleep apnea can affect blood pressure and vascular health. Menopause can alter lipid metabolism and body composition. Muscle mass affects glucose disposal. Smoking changes vascular biology. Exercise influences nearly all of them.

This is why preventive cardiology at HormoneSynergy® is integrated with metabolic health, body composition, hormone evaluation when appropriate, sleep, exercise, nutrition, and broader longevity planning.

For patients who want a comprehensive baseline across these systems, the Optimal Aging Assessment provides a structured starting point that includes advanced cardiovascular and metabolic laboratory testing, body composition assessment, vascular screening, and physician interpretation.

Why Choose HormoneSynergy®?

Dr. Kathryn Retzler has practiced integrative and longevity-focused medicine for more than 25 years and has completed two preventive cardiology fellowships through the American Academy of Anti-Aging Medicine with Mark Houston, MD.

Our cardiovascular approach reflects the same model used throughout HormoneSynergy®: measure what is useful, understand the physiology behind it, and use the information to make better clinical decisions.

Advanced testing is valuable when it answers a meaningful question. It is not valuable simply because it is advanced.

Preventive Cardiology Resources

Start With the Right Level of Cardiovascular Evaluation

Some people need a broad preventive baseline. Others have a specific question about elevated ApoB, Lp(a), a changing calcium score, family history, or possible coronary plaque.

If you are not sure which level of evaluation makes sense, our team can help you understand the available options before you schedule testing.

Frequently Asked Questions

What is preventive cardiology?

Preventive cardiology focuses on identifying and reducing cardiovascular risk before a heart attack, stroke, or other major cardiovascular event occurs. Evaluation may include laboratory testing, blood pressure and metabolic assessment, lifestyle review, and vascular or coronary imaging when appropriate.

What is ApoB and why does it matter?

ApoB estimates the number of circulating atherogenic lipoprotein particles, including LDL, IDL, VLDL remnants, and lipoprotein(a). It can identify particle burden that is not always apparent from LDL-C alone.

Can ApoB be high even if my triglycerides and fasting insulin are good?

Yes. Good metabolic health is favorable, but it does not guarantee a low ApoB. Some metabolically healthy people have markedly elevated LDL-C and ApoB due to genetics, diet response, or other lipid physiology.

What is Lp(a)?

Lipoprotein(a), or Lp(a), is a largely inherited ApoB-containing lipoprotein associated with cardiovascular risk. It is not included in most standard cholesterol panels.

What is the difference between CAC and CCTA?

A CAC scan is a noncontrast CT that detects calcified coronary plaque. CCTA uses intravenous contrast to visualize the coronary arteries and can identify both calcified and noncalcified plaque as well as coronary narrowing.

Is Cleerly® the same as a CCTA?

No. CCTA is the imaging examination. Cleerly® is an AI-assisted analysis performed on suitable CCTA images to quantify and characterize coronary plaque.

Can someone have coronary plaque with a calcium score of zero?

Yes. A zero CAC score means no calcified plaque was detected. Noncalcified plaque can still be present, particularly in younger patients and selected higher-risk individuals.

What does carotid ultrasound add?

Carotid ultrasound can identify carotid plaque and measure arterial wall thickness. It provides information about vascular disease in a different arterial territory and can complement laboratory risk assessment.

Does good metabolic health make high LDL or ApoB harmless?

No. Good insulin sensitivity, normal blood pressure, physical fitness, low visceral fat, and low triglycerides are all favorable. They reduce important sources of cardiovascular risk, but current evidence does not show that they eliminate the long-term significance of markedly elevated ApoB exposure.

Does HormoneSynergy® automatically recommend statins for high cholesterol?

No. Treatment decisions are individualized. The degree and duration of LDL-C and ApoB elevation, Lp(a), family history, metabolic health, blood pressure, smoking, existing plaque, medication tolerance, and overall cardiovascular risk all contribute to the decision.

How does preventive cardiology connect with longevity medicine?

Cardiovascular health is closely connected with insulin sensitivity, body composition, inflammation, sleep, exercise, nutrition, hormone transitions, and other systems that influence healthspan. Preventive cardiology is therefore part of the broader HormoneSynergy® longevity medicine model rather than an isolated cholesterol program.

References

• 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
• 2026 ACC/AHA Guideline on the Management of Dyslipidemia — Circulation
• HormoneSynergy®: CAC vs CCTA vs Cleerly® Plaque Analysis

Editorial Transparency

This page is educational and does not replace individualized medical evaluation. Cardiovascular testing and treatment should be selected according to the patient’s medical history, symptoms, laboratory findings, family history, prior imaging, medications, and overall clinical context. Advanced testing is most useful when the result is likely to clarify risk or change management.